AbbVie has announced a $195-million investment in its North Chicago, Illinois, manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the US.  

This expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of capital in the US over the next decade to broadly support innovation and expand critical manufacturing capabilities and capacity. 

The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the US to support domestic production of neuroscience, immunology, and oncology medicines. Construction of the new North Chicago API facility will begin in the fall 2025, with the site projected to be fully operational in 2027. The facility will expand AbbVie’s existing US manufacturing footprint, which includes 11 manufacturing sites.  

Source: AbbVie